Immunotherapy Strategies for Gastrointestinal Stromal Tumor.
GIST
antibodies
checkpoint inhibitors
cytokine
gastrointestinal stromal tumors
immunotherapy
lymphocytes
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
14 Jul 2021
14 Jul 2021
Historique:
received:
19
05
2021
revised:
06
07
2021
accepted:
06
07
2021
entrez:
24
7
2021
pubmed:
25
7
2021
medline:
25
7
2021
Statut:
epublish
Résumé
Gastrointestinal stromal tumors (GIST) are the most common mesenchymal soft tissue sarcoma of the gastrointestinal tract. The management of locally advanced or metastatic unresectable GIST involves detecting KIT, PDGFR, or other molecular alterations targeted by imatinib and other tyrosine kinase inhibitors. The role of immunotherapy in soft tissue sarcomas is growing fast due to multiple clinical and pre-clinical studies with no current standard of care. The potential therapies include cytokine-based therapy, immune checkpoint inhibitors, anti-KIT monoclonal antibodies, bi-specific monoclonal antibodies, and cell-based therapies. Here we provide a comprehensive review of the immunotherapeutic strategies for GIST.
Identifiants
pubmed: 34298737
pii: cancers13143525
doi: 10.3390/cancers13143525
pmc: PMC8306810
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
J Clin Invest. 2017 Aug 1;127(8):2930-2940
pubmed: 28650338
Cancer Immunol Immunother. 2012 Jul;61(7):1113-24
pubmed: 22198309
Expert Rev Anticancer Ther. 2014 Dec;14(12):1445-59
pubmed: 25340579
Clin Cancer Res. 2017 Jan 15;23(2):454-465
pubmed: 27470968
Clin Cancer Res. 2018 Sep 1;24(17):4297-4308
pubmed: 29764854
J Immunol Res. 2016;2016:4273943
pubmed: 28116316
Cancer Gene Ther. 2017 Mar;24(3):130-133
pubmed: 28186088
Pharmacogenomics. 2020 Mar;21(4):231-234
pubmed: 31973655
Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3501-6
pubmed: 23382202
J Clin Oncol. 2008 Nov 20;26(33):5360-7
pubmed: 18955451
J Natl Compr Canc Netw. 2010 Apr;8 Suppl 2:S1-41; quiz S42-4
pubmed: 20457867
J Med Genet. 2013 Oct;50(10):653-61
pubmed: 23833252
J Clin Invest. 2019 Feb 14;129(5):1863-1877
pubmed: 30762585
Clin Cancer Res. 2017 Jun 15;23(12):2972-2980
pubmed: 28007774
Oncoimmunology. 2015 Feb 3;4(5):e1002729
pubmed: 26155391
J Immunother Cancer. 2019 Aug 8;7(1):213
pubmed: 31395100
Int J Clin Exp Pathol. 2014 Jun 15;7(7):3563-79
pubmed: 25120735
Curr Opin Oncol. 2015 Jul;27(4):338-42
pubmed: 26049274
Gastric Cancer. 2016 Jan;19(1):3-14
pubmed: 26276366
Nat Med. 2011 Aug 28;17(9):1094-100
pubmed: 21873989
Nat Immunol. 2002 Nov;3(11):991-8
pubmed: 12407406
J Natl Compr Canc Netw. 2015 May;13(5 Suppl):670-2
pubmed: 25995426
Int J Cancer. 2010 Aug 15;127(4):899-909
pubmed: 20013807
Am J Transl Res. 2014 Nov 22;6(6):831-40
pubmed: 25628793
Cancers (Basel). 2021 Jan 19;13(2):
pubmed: 33478080
J Transl Med. 2013 Feb 21;11:46
pubmed: 23433424
Cancer Res. 2013 Jun 15;73(12):3499-510
pubmed: 23592754
J Clin Pharmacol. 2015 Aug;55(8):920-5
pubmed: 25810235
Hematol Oncol Clin North Am. 2013 Oct;27(5):905-20
pubmed: 24093167
Adv Anat Pathol. 2017 Sep;24(5):259-267
pubmed: 28632504
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Nat Med. 2011 Jun;17(6):700-7
pubmed: 21552268
J Clin Oncol. 2017 May 20;35(15):1713-1720
pubmed: 28362562